Mindfully Curated
Scientists have uncovered evidence that serotonin, the chemical best known for regulating mood, may also speed the progression of a common heart valve disease in some people. The research suggests that patients with degenerative mitral regurgitation wh…
Gold may have a secret self-defense system that helps it resist tarnishing. Researchers discovered that atoms on gold surfaces reorganize themselves into patterns that block oxygen from reacting with the metal, suppressing oxidation by up to a trillion…
Yale scientists discovered two neuron surface proteins that appear to help spread the toxic protein linked to Parkinson’s disease. Blocking these proteins in mice dramatically reduced disease progression, offering a potential new target for future ther…
Researchers found that the common blood pressure drug telmisartan can significantly improve the performance of the cancer drug olaparib, potentially expanding its benefits beyond patients with BRCA-related tumors. The combination is already being teste…
AppLovin’s revenue has grown 2.5x in two years while Fastly sees a more modest uptick.
The cybersecurity stock has soared 69% this year.
The pullback in the DRAM – Roundhill Memory ETF could be a buying opportunity.
Home Depot’s revenue consistently outpaces Lowe’s by roughly double, yet both retailers show stable seasonal patterns.
The Nasdaq-100 listing is one thing, but the forthcoming lock-up expiry dates are another.
Acadia Pharmaceuticals specializes in CNS therapies; a key insider recently trimmed their stake amid ongoing product pipeline developments.
Your hard-earned money would be better spent elsewhere.
Investors are trying to figure out how macroeconomic forces affect the world’s top cryptocurrency.
As a whole, investors are betting big on AI and other tech innovations.
NuScale Power, a leader in modular nuclear technology, reported a notable insider sale amid ongoing industry and company developments.
These two AI stocks have struggled lately, but their solid earnings growth potential suggests they can step on the gas again.
Don’t assume you’re a lost cause.
The ETF sector started out with broadly diversified products, but it has increasingly offered riskier, more focused offerings.
Fidelity has a lower expense ratio but Vanguard sports massive scale.
They won’t necessarily sidestep volatility if and when it ramps up, but all of these businesses remain marketable regardless of the economic backdrop or the broad market’s direction.
The new developments will likely have broad implications that investors need to prepare for.